Gene · 11251
PTGDR2: prostaglandin D2 receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PTGDR2: prostaglandin D2 receptor 2. Genes, record 11251. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/11251
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y5Y4 | Prostaglandin D2 receptor 2 | 395 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents32
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 5726 | Q9Y5Y4 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 323 | Q9Y5Y4 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3618 | Q9Y5Y4 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3618 | Q9Y5Y4 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5726 | Q9Y5Y4 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 323 | Q9Y5Y4 | Espacenet |
| EP 4491229 A2 | 2025-01-15 | 205 | Q9Y5Y4 | Espacenet |
| WO 2024230934 A1 | 2024-11-14 | 330 | Q9Y5Y4 | Espacenet |
| JP 2023153821 A | 2023-10-18 | 36 | Q9Y5Y4 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67447 | Q9Y5Y4 | Espacenet |
1 to 10 of 32
See all 32 patentsDrugs16
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADC3680 | CHEMBL3545343 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| AM-211 | CHEMBL2181753 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| AM-461 | CHEMBL5095021 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| ARRY-502 | CHEMBL5314403 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| AZD1981 | CHEMBL1914489 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| BI-671800 | CHEMBL551813 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| DONITRIPTAN | CHEMBL1742428 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| FEVIPIPRANT | CHEMBL3137332 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| MK-1029 | CHEMBL3545031 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
| MK-7246 | CHEMBL561132 | G protein-coupled receptor 44 antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 16
See all 16 drugsTrials53
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05706454 | RAMATROBAN | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04049175 | TIMAPIPRANT | PHASE3 | ClinicalTrials.gov | |
| NCT03989635 | FEVIPIPRANT | PHASE2 | ClinicalTrials.gov | |
| NCT03810183 | FEVIPIPRANT | PHASE2 | 2021-01-25 | ClinicalTrials.gov |
| NCT03681093 | FEVIPIPRANT | PHASE3 | 2021-01-05 | ClinicalTrials.gov |
| NCT03650400 | FEVIPIPRANT | PHASE2 | 2020-07-20 | ClinicalTrials.gov |
| NCT03629249 | FEVIPIPRANT | PHASE3 | 2021-02-02 | ClinicalTrials.gov |
| NCT03226392 | FEVIPIPRANT | PHASE3 | 2020-02-28 | ClinicalTrials.gov |
| NCT03215758 | FEVIPIPRANT | PHASE3 | 2020-02-12 | ClinicalTrials.gov |
| NCT03052517 | FEVIPIPRANT | PHASE3 | 2020-10-12 | ClinicalTrials.gov |
1 to 10 of 53
See all 53 trialsNIH grants1,296
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PTGDR2 papers | Newest fiscal year |
|---|---|---|---|
| U19AI070535 | Airway Inflammation and Airway Remodeling in Severe Asthma | 12 | 2025 |
| U19AI070235 | Epithelial Genes in Allergic Inflammation | 11 | 2025 |
| U01AI095608 | Regulation of mucosal immunity by neuronal pathways | 10 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 9 | 2025 |
| P30ES007048 | Environmental Exposures, Host Factors and Human Disease | 9 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 7 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 7 | 2025 |
| R01AI124355 | Genetic and Immunological Dissection of Eosinophilic Esophagitis | 7 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 6 | 2025 |
| R01CA208353 | Elucidation of Human Natural Killer Cell Development | 6 | 2025 |
1 to 10 of 1,296Source NIH's project files
See all 1,296 nih grantsPapers2,267
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunometabolic Profiling of T Cells and Innate Lymphoid Cells Uncovers Therapeutic Targets to Enhance Immunotherapy in Head and Neck Cancer. | Cancer Immunol Res | 2026 | 42804348 | PubTator, text mining | PubMed |
| Machine learning reveals immune heterogeneity in recovery-phase samples of pediatric wheezing. | Front Pediatr | 2026 | 42707154 | PubTator, text mining | PubMed |
| A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy. | Clin Immunol | 2026 | 42379330 | PubTator, text mining | PubMed |
| The Pivotal Role of Plant Derivatives and Eicosanoid Signaling Modulation in Counteracting Cardiomiopathy. | Int J Mol Sci | 2026 | 42278379 | PubTator, text mining | PubMed |
| Stage-dependent interaction between circulating and tissue-resident memory CD4+ T cells in recurrent allergic airway inflammation. | Inflamm Res | 2026 | 42228188 | PubTator, text mining | PubMed |
| The PGD2/DP2 axis promotes pro-inflammatory responses but attenuates an antigen-presenting role of human basophils. | Commun Biol | 2026 | 42162122 | PubTator, text mining | PubMed |
| Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 Blockade. | Thorac Cancer | 2026 | 41920053 | PubTator, text mining | PubMed |
| IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression. | Inflamm Res | 2026 | 41917320 | PubTator, text mining | PubMed |
| Involvement of increased arginase-1+ group 2 innate lymphoid cells and myeloid-derived suppressor cells in endometrial carcinoma: A pilot study. | J Int Med Res | 2026 | 41912235 | PubTator, text mining | PubMed |
| Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation. | Nat Commun | 2026 | 41896575 | PubTator, text mining | PubMed |
1 to 10 of 2,267
See all 2,267 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/11251
GET https://conductscience.org/api/genes/v1/11251/patents?page=2